cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amgen Inc
224 own
69 watching
Current Price
$335.26
$2.81
(0.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
169,062.5M
52-Week High
52-Week High
346.85001
52-Week Low
52-Week Low
249.70000
Average Volume
Average Volume
2.34M
Dividend Yield
Dividend Yield
0.032184
P/E Ratio
P/E Ratio
21.7238
iconMarket Capitalization169,062.5M
icon52-Week High346.85001
icon52-Week Low249.70000
iconAverage Volume2.34M
iconDividend Yield0.032184
iconP/E Ratio21.7238
What does the Amgen Inc do?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human epidermal growth factor receptor 2-positive early breast cancer. The company's other marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products for use to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
How much money does Amgen Inc make?
News & Events about Amgen Inc.
InvestorPlace
1 year ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Zolmax
1 year ago
Byrne Asset Management LLC lifted its position in Amgen Inc. (NASDAQ:AMGN Get Rating) by 22.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,166 shares of the medical research companys stock after acquiring an ...
PR Newswire
1 year ago
FDA GRANTS FULL APPROVAL FOR BLINCYTO (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA FDA GRANTS FULL APPROVAL FOR BLINCYTO (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PR Newswire...
Ticker Report
1 year ago
Mission Wealth Management LP raised its stake in Amgen Inc. (NASDAQ:AMGN Get Rating) by 2.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,073 shares of the medical research companys stock after ...
Ticker Report
1 year ago
Cedar Brook Financial Partners LLC reduced its holdings in Amgen Inc. (NASDAQ:AMGN Get Rating) by 11.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 903 shares of the medical research companys stock ...
Frequently Asked Questions
Frequently Asked Questions
What is Amgen Inc share price today?
plus_minus_icon
Can Indians buy Amgen Inc shares?
plus_minus_icon
How can I buy Amgen Inc shares from India?
plus_minus_icon
Can Fractional shares of Amgen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amgen Inc stocks?
plus_minus_icon
What is today’s traded volume of Amgen Inc?
plus_minus_icon
What is today’s market capitalisation of Amgen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amgen Inc?
plus_minus_icon
What percentage is Amgen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amgen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$335.26
$2.81
(0.85%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Merck & Co. Inc.
Merck & Co. Inc.
$117.96
$2.10 (1.81 %)
Medtronic PLC
Medtronic PLC
$90.10
$0.10 (0.11 %)
General Electric Company
General Electric Company
$181.44
$3.16 (1.77 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$49.99
$0.86 (1.75 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Merck & Co. Inc.
Merck & Co. Inc.
$117.96
$2.10 (1.81 %)
Medtronic PLC
Medtronic PLC
$90.10
$0.10 (0.11 %)
General Electric Company
General Electric Company
$181.44
$3.16 (1.77 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$49.99
$0.86 (1.75 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00